Cargando…

Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab

PURPOSE: In a benchwork particle counting analytical evaluation, the number and type of particles in intravitreal injection formulations of three different agents against vascular endothelial growth factor were investigated. METHODS: Commercially available ready-to-use aflibercept and brolucizumab g...

Descripción completa

Detalles Bibliográficos
Autores principales: Schargus, Marc, Kopp, Katharina Tatjana, Helbig, Constanze, Frings, Andreas, Winter, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375009/
https://www.ncbi.nlm.nih.gov/pubmed/34406342
http://dx.doi.org/10.1167/tvst.10.9.21
_version_ 1783740235140562944
author Schargus, Marc
Kopp, Katharina Tatjana
Helbig, Constanze
Frings, Andreas
Winter, Gerhard
author_facet Schargus, Marc
Kopp, Katharina Tatjana
Helbig, Constanze
Frings, Andreas
Winter, Gerhard
author_sort Schargus, Marc
collection PubMed
description PURPOSE: In a benchwork particle counting analytical evaluation, the number and type of particles in intravitreal injection formulations of three different agents against vascular endothelial growth factor were investigated. METHODS: Commercially available ready-to-use aflibercept and brolucizumab glass syringes, vials containing bevacizumab (off-label use in ophthalmology), and repackaged ready-to-use plastic syringes containing bevacizumab were tested without filtration. Total visible, subvisible, and nanoparticles numbers and size distributions were quantified using light obscuration, flow imaging, resonant mass measurement (RMM), tunable resistive pulse sensing, and dynamic light scattering. RESULTS: Repackaged bevacizumab showed overall low particle numbers, aflibercept showed high numbers of micrometer sized particles but low nanoparticle numbers, brolucizumab showed low to moderate numbers of micrometer sized particles but high nanoparticle numbers. RMM measurements identified particles in the nanometer range as either proteinaceous or silicon oil; the nature of the other particles was not further evaluated. CONCLUSIONS: Repackaged bevacizumab shows no inferior particle quality compared to ready-to-use products. It is relevant to study nanoparticle load of the products as the micrometer-sized particle numbers do not in all cases correlate to nanoparticle counts. Particularly for the high concentration product Beovu (brolucizumab), high nanoparticle numbers were found despite low numbers of micrometer sized particles. Silicone oil droplets did not account for high particle numbers as the measured numbers were low. TRANSLATIONAL RELEVANCE: Different side effects are registered in different frequencies with different intravitreal anti-VEGF-drugs and syringes, which are applied by injection by small 30G needles through the sclera directly to the intravitreal cavity. The study of nanoparticles and silicone oil droplets may be able to contribute to narrowing down the causes.
format Online
Article
Text
id pubmed-8375009
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Association for Research in Vision and Ophthalmology
record_format MEDLINE/PubMed
spelling pubmed-83750092021-08-26 Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab Schargus, Marc Kopp, Katharina Tatjana Helbig, Constanze Frings, Andreas Winter, Gerhard Transl Vis Sci Technol Article PURPOSE: In a benchwork particle counting analytical evaluation, the number and type of particles in intravitreal injection formulations of three different agents against vascular endothelial growth factor were investigated. METHODS: Commercially available ready-to-use aflibercept and brolucizumab glass syringes, vials containing bevacizumab (off-label use in ophthalmology), and repackaged ready-to-use plastic syringes containing bevacizumab were tested without filtration. Total visible, subvisible, and nanoparticles numbers and size distributions were quantified using light obscuration, flow imaging, resonant mass measurement (RMM), tunable resistive pulse sensing, and dynamic light scattering. RESULTS: Repackaged bevacizumab showed overall low particle numbers, aflibercept showed high numbers of micrometer sized particles but low nanoparticle numbers, brolucizumab showed low to moderate numbers of micrometer sized particles but high nanoparticle numbers. RMM measurements identified particles in the nanometer range as either proteinaceous or silicon oil; the nature of the other particles was not further evaluated. CONCLUSIONS: Repackaged bevacizumab shows no inferior particle quality compared to ready-to-use products. It is relevant to study nanoparticle load of the products as the micrometer-sized particle numbers do not in all cases correlate to nanoparticle counts. Particularly for the high concentration product Beovu (brolucizumab), high nanoparticle numbers were found despite low numbers of micrometer sized particles. Silicone oil droplets did not account for high particle numbers as the measured numbers were low. TRANSLATIONAL RELEVANCE: Different side effects are registered in different frequencies with different intravitreal anti-VEGF-drugs and syringes, which are applied by injection by small 30G needles through the sclera directly to the intravitreal cavity. The study of nanoparticles and silicone oil droplets may be able to contribute to narrowing down the causes. The Association for Research in Vision and Ophthalmology 2021-08-18 /pmc/articles/PMC8375009/ /pubmed/34406342 http://dx.doi.org/10.1167/tvst.10.9.21 Text en Copyright 2021 The Authors https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License.
spellingShingle Article
Schargus, Marc
Kopp, Katharina Tatjana
Helbig, Constanze
Frings, Andreas
Winter, Gerhard
Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
title Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
title_full Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
title_fullStr Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
title_full_unstemmed Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
title_short Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
title_sort comparison of syringes with intravitreal anti-vegf drugs: particle burden and protein aggregates in brolucizumab, aflibercept and bevacizumab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375009/
https://www.ncbi.nlm.nih.gov/pubmed/34406342
http://dx.doi.org/10.1167/tvst.10.9.21
work_keys_str_mv AT schargusmarc comparisonofsyringeswithintravitrealantivegfdrugsparticleburdenandproteinaggregatesinbrolucizumabafliberceptandbevacizumab
AT koppkatharinatatjana comparisonofsyringeswithintravitrealantivegfdrugsparticleburdenandproteinaggregatesinbrolucizumabafliberceptandbevacizumab
AT helbigconstanze comparisonofsyringeswithintravitrealantivegfdrugsparticleburdenandproteinaggregatesinbrolucizumabafliberceptandbevacizumab
AT fringsandreas comparisonofsyringeswithintravitrealantivegfdrugsparticleburdenandproteinaggregatesinbrolucizumabafliberceptandbevacizumab
AT wintergerhard comparisonofsyringeswithintravitrealantivegfdrugsparticleburdenandproteinaggregatesinbrolucizumabafliberceptandbevacizumab